MedTrace Logo

Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762190 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2012-11-12

No results posted yet for this study

Summary

The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus.

Conditions

Interventions

DRUG

TAK-559 and insulin

TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

DRUG

Insulin

TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

Sponsors & Collaborators

Principal Investigators

  • VP Biological Sciences · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2004-12-31
Completion
2004-12-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00762190 on ClinicalTrials.gov